Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence Now Available. Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline

globenewswire.com
INO Inovio is mentioned as a leading cancer vaccine developer tracked by the Cancer Vaccines Analytical Tool. The article does not provide specific sentiment regarding its performance or prospects. BNTX BioNTech is listed as a leading cancer vaccine developer tracked by the Cancer Vaccines Analytical Tool. The article does not offer specific sentiment about the company's current standing or future outlook. GSK GlaxoSmithKline is identified as a leading cancer vaccine developer tracked by the Cancer Vaccines Analytical Tool. The article does not express a specific sentiment towards the company.

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence Now Available. Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence" has been added to ResearchAndMarkets.com's offering.

Cancer Vaccines Analytical Tool Advances Oncology Pipeline Intelligence and Strategic Decision-Making

The Cancer Vaccines Analytical Tool provides comprehensive, continuously updated intelligence for organizations navigating the rapidly evolving cancer vaccine market. Designed for oncology drug developers, biotechnology companies, pharmaceutical organizations, investors, academic institutions, and business development teams, the platform combines competitive intelligence, clinical trial analytics, licensing data, and pipeline tracking in one web-based resource.

During 2024 and 2025, the oncology pipeline recorded 76 new cancer vaccines, more than 300 drugs associated with key events, and 1,946 events across 1,412 drug programs. This accelerating activity highlights the need for reliable, near-real-time intelligence to identify emerging technologies, evaluate competitors, monitor clinical progress, and uncover strategic opportunities.

Comprehensive Cancer Vaccine Market Intelligence

The Cancer Vaccines Analytical Tool tracks innovation across personalized neoantigen vaccines, armored vaccine technologies, mRNA platforms, combination immunotherapies, artificial intelligence, multi-omics, and next-generation sequencing. These developments are supporting increasingly precise therapeutic strategies, stronger immune responses, scalable development, and sustained antitumor activity.

Users can apply the platform's oncology intelligence to:

Continuous platform updates and monthly email alerts help users remain informed about new drugs, clinical trials, targets, companies, deals, biomarkers, and other significant developments. Unlike static market reports, the tool includes a full year of online access, new features, pipeline alerts, training resources, and dedicated support.

Advanced Oncology Clinical and Competitive Intelligence

Powered by an award-winning, AI-enhanced intelligence platform with more than 25 years of oncology expertise, the Cancer Vaccines Analytical Tool supports decisions throughout oncology drug development. Its global coverage spans start-ups, established biotechnology companies, pharmaceutical organizations, academic institutions, technologies, targets, and commercial opportunities.

The platform includes licensing contacts, a worldwide investor network, historical deal information, and academic-commercial projects. Clinical development intelligence covers more than 3,000 biomarkers, including stratifying, predictive, and pharmacodynamic markers, as well as companion diagnostic programs from early development through approval.

Clinical trial coverage extends beyond primary endpoints to include dosage, resistance mechanisms, adverse events, food effects, trial phase and status, first-in-human studies, tumor stage and grade, and line of therapy. Combination therapy analytics also organize targets, modalities, indications, and development stages, enabling users to assess evolving oncology treatment strategies efficiently.

Real-world evidence and multi-point analytics can be segmented by development stage, drug modality, co-medication profile, or biomarker cluster. These capabilities support contextual analysis and evidence-based decisions across cancer vaccine research, clinical development, business development, licensing, and investment.

Coverage at a Glance

Leading cancer vaccine developers tracked by the platform include OncoTherapy Science, Inovio, BioNTech, Theravectys, and GlaxoSmithKline. The most active nations represented include the United States, China, the United Kingdom, France, and Germany.

Flexible Access and Ongoing Support

The Cancer Vaccines Analytical Tool is a web-based application compatible with major modern browsers, including Chrome, Firefox, and Safari. Internet access is required. Users also receive 24/7 support, how-to training videos, practical case studies, and guidance for competitive pipeline analysis and business development.

Organizations seeking broader oncology intelligence can renew access or upgrade to 1stOncology, a full-service platform supporting oncology research, clinical development, competitive analysis, licensing, partnerships, and strategic decision-making.

Companies Featured

For more information about this directory visit https://www.researchandmarkets.com/r/reu5qd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.